ThermaClear
This article was originally published in The Rose Sheet
Executive Summary
FDA has given clearance to Therative to market its ThermaClear hand-held acne treatment device, the company announces Jan. 16. Therative has also finished an additional round of expansion funding in anticipation of the product's launch, raising $5 mil. from three venture capital firms. ThermaClear is designed for home treatment of mild-to-moderate acne. It utilizes proprietary technology based on the laser treatments used by dermatologists. The device wears the start-up's first consumer brand; it will be launched in a line that includes a number of topical acne treatment products...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.